Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CATAFLU.OR

Financiado

Cerrado

OrganoCATAlytic approaches towards easily synthesized economical and high yiel...

OrganoCATAlytic approaches towards easily synthesized economical and high yielding oseltamivir derivatives Despite widespread immunization, influenza still kills thousand of people, and costs to US, Europe and Asia enormous amount of money in term of healthcare expenses and productivity losses. While immunization remains an important a... ver más

30/09/2011

UNIBO

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-09-30 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

UNIBO

0.00€ | Lider

UK BA

N.D. | Participante

UNIVERSITAT ZU KOLN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NAINH The Development of Mechanism Based Inhibitors of Influenza N... 172K€ Cerrado

PANVIPREP Developing broad-spectrum antiviral drugs for pandemic prepa... 8M€ Cerrado

FLUCURE Development of novel antiviral drugs against Influenza 8M€ Cerrado

FLU-PHARM New drugs targeting influenza virus polymerase 8M€ Cerrado

ANTIFLU Innovative anti influenza drugs excluding viral escape 8M€ Cerrado

DESARROLLO DE NUEVAS ACTIVIDADES INVESTIGADOR... DESARROLLO DE NUEVAS ACTIVIDADES INVESTIGADORAS EN FASE LATE... 1M€ Cerrado

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite widespread immunization, influenza still kills thousand of people, and costs to US, Europe and Asia enormous amount of money in term of healthcare expenses and productivity losses. While immunization remains an important approach to prevent influenza, small-molecule antiviral agents represent a novel opportunity for effective prevention and therapy of flu. Inhibitors of neuraminidase, essential enzyme for viral replication in all three classes of influenza viruses, has been recently found. Two of these inhibitors have reached the market, namely, zanamivir (GSKBs Relenza (1) in July 1999, and oseltamivir phosphate (Gilead Bs Tamiflu (2), also marketed by Roche) in October 1999. The recent healthy problem related to avian flu, has increase the public demand for stockpiles of Tamiflu, both as a reasonable frontline therapy against a possible flu pandemic and as a preventive agent. However, natural sources of drug (Shikimic acid) are scarcely, and increasing demand for oseltamivir phosphate has placed further pressure on Roche and the chemical community in general to develop new routes to the drug that do not involve complex natural products. In addition, the described synthesis are expensive and difficult. Moreover, in this synthesis use of hazardous azide-based reagents was necessary. New routes to Tamiflu have been recently described, but more than 12 steps in one case and 17 in another are needed. In order to find new drug candidates, cut the drug costs and improving availability as well as efficiency, new chemical synthesis are necessary. We propose a new domino reaction based on an organocatalytic approach to the synthesis of new Tamiflu derivatives. The chemistry involved in this project is easy to perform, and well adapt to industrial contest. Moreover, new chemical structures will be prepared and evaluated as potential drug against virulent and mutated flu viruses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores